Successful VLAIO R&D Grant Application!
Trince received a VLAIO R&D grant to support activities for further developing its novel intracellular delivery technology towards clinical cell-based therapeutic applications. The project runs until April 2025 and has three main objectives:
(1) Successful engineering of human T cells with large effector molecules (plasmids, mRNA and CRISPR/Cas9 RNPs) while preserving T cell fitness and therapeutic efficacy, (2) Develop a prototype device for automated high-throughput transfection of T cells based on Trince’s proprietary photoporation technology and, (3) Successful internal and external evaluation of the automated high-throughput prototype device.
Cell & Gene Therapy Insights – Trince spotlight
Trince is included in the “Emerging technologies & companies in cell & gene therapy manufacturing” review in the Tools of tomorrow issue of Cell & Gene Therapy insights.
Emilie Viey joins Trince as COO
We are delighted to welcome Emilie Viey, PhD to the Trince team as our new Chief Commercial Officer.
White paper with Revatis
Together with Revatis, we successfully used our LumiPore transfection platform to deliver macromolecules into equine and human mesenchymal stem cells.
Clarivate included our co-founders in Highly Cited Researchers list of 2022
We are proud to announce that Clarivate has included both our scientific co-founders in their prestigious list of Highly Cited Researchers for 2022.
82 citations one year after publication
With 82 citations within one year after publication, our Nature Nanotechnology tpaper has received the status of Hot Paper by Web of Science.